Idrocilamide

Idrocilamide
Clinical data
Trade names	Talval, Srilane, Relaxnova, Brolitène
AHFS/Drugs.com	International Drug Names
Routes of; administration	Topical
ATC code	M02AX05 (WHO) ;
Identifiers
	IUPAC name N-(2-Hydroxyethyl)-3-phenyl-2-propenamide;
CAS Number	6961-46-2 ;
PubChem CID	1550874;
ChemSpider	1267352 ;
UNII	6C816LUB1O;
ChEMBL	ChEMBL102358 ;
CompTox Dashboard (EPA)	DTXSID8046404 ;
ECHA InfoCard	100.027.414
Chemical and physical data
Formula	C11H13NO2
Molar mass	191.230 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(\C=C\c1ccccc1)NCCO;
	InChI InChI=1S/C11H13NO2/c13-9-8-12-11(14)7-6-10-4-2-1-3-5-10/h1-7,13H,8-9H2,(H,12,14)/b7-6+ ; Key:OSCTXCOERRNGLW-VOTSOKGWSA-N ;
	(what is this?) (verify)

Idrocilamide (trade names Talval, Srilane, Relaxnova, Brolitène[1]) is a medication with skeletal muscle relaxant[2] and anti-inflammatory actions[3] used as a topical cream to treat lumbago and other kinds of muscular pain;[4] it is available on prescription or over-the-counter in France and various other countries.[1]

Interactions

Idrocilamide has been reported to be a potent inhibitor of the metabolism of caffeine.[5][6]

References

Drugs.com: International Drug Names
Bouron A, Rivet M, Nasri-Sebdani M, Guillemain J, Durbin P, Guerrier D, Raymond G (1990). "The direct depressant effect of LCB29 (idrocilamide) on mechanical tension of rat soleus muscle fibers". Canadian Journal of Physiology and Pharmacology. 68 (12): 1503–1509. doi:10.1139/y90-228. PMID 2085796.
Bannwarth B, Le Huec JC, Vinçon G, Labat L, Demotes-Mainard F, Rivaille F, Le Rebeller A (1993). "[Tissue and systemic diffusion of idrocilamide after cutaneous administration]". Revue du Rhumatisme (in French). 60 (12): 932–6. PMID 8012322.
Stehman M, Lehert P (1990). "Clinical double-blind study with idrocilamide ointment in the treatment of acute lumbago". Acta Belgica. Medica Physica. 13 (1): 29–32. PMID 2140002.
Carrillo JA, Benitez J (2000). "Clinically significant pharmacokinetic interactions between dietary caffeine and medications". Clinical Pharmacokinetics. 39 (2): 127–53. doi:10.2165/00003088-200039020-00004. PMID 10976659.
Brazier JL, Descotes J, Lery N, Ollagnier M, Evreux JC (1980). "Inhibition by idrocilamide of the disposition of caffeine". European Journal of Clinical Pharmacology. 17 (1): 37–43. doi:10.1007/bf00561675. PMID 7371698.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[Drugs.com-1] Drugs.com: International Drug Names

[2] Bouron A, Rivet M, Nasri-Sebdani M, Guillemain J, Durbin P, Guerrier D, Raymond G (1990). "The direct depressant effect of LCB29 (idrocilamide) on mechanical tension of rat soleus muscle fibers". Canadian Journal of Physiology and Pharmacology. 68 (12): 1503–1509. doi:10.1139/y90-228. PMID 2085796.

[pmid8012322-3] Bannwarth B, Le Huec JC, Vinçon G, Labat L, Demotes-Mainard F, Rivaille F, Le Rebeller A (1993). "[Tissue and systemic diffusion of idrocilamide after cutaneous administration]". Revue du Rhumatisme (in French). 60 (12): 932–6. PMID 8012322.

[4] Stehman M, Lehert P (1990). "Clinical double-blind study with idrocilamide ointment in the treatment of acute lumbago". Acta Belgica. Medica Physica. 13 (1): 29–32. PMID 2140002.

[pmid10976659-5] Carrillo JA, Benitez J (2000). "Clinically significant pharmacokinetic interactions between dietary caffeine and medications". Clinical Pharmacokinetics. 39 (2): 127–53. doi:10.2165/00003088-200039020-00004. PMID 10976659.

[pmid7371698-6] Brazier JL, Descotes J, Lery N, Ollagnier M, Evreux JC (1980). "Inhibition by idrocilamide of the disposition of caffeine". European Journal of Clinical Pharmacology. 17 (1): 37–43. doi:10.1007/bf00561675. PMID 7371698.